These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 28619071

  • 61. Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.
    Fonseca JA, McCaffery JN, Caceres J, Kashentseva E, Singh B, Dmitriev IP, Curiel DT, Moreno A.
    Vaccine; 2018 May 11; 36(20):2799-2808. PubMed ID: 29657070
    [Abstract] [Full Text] [Related]

  • 62. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy.
    Chinchilla M, Pasetti MF, Medina-Moreno S, Wang JY, Gomez-Duarte OG, Stout R, Levine MM, Galen JE.
    Infect Immun; 2007 Aug 11; 75(8):3769-79. PubMed ID: 17502396
    [Abstract] [Full Text] [Related]

  • 63. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.
    Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, Draper SJ.
    Vaccine; 2010 Oct 18; 28(44):7167-78. PubMed ID: 20937436
    [Abstract] [Full Text] [Related]

  • 64. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.
    Jones RM, Chichester JA, Mett V, Jaje J, Tottey S, Manceva S, Casta LJ, Gibbs SK, Musiychuk K, Shamloul M, Norikane J, Mett V, Streatfield SJ, van de Vegte-Bolmer M, Roeffen W, Sauerwein RW, Yusibov V.
    PLoS One; 2013 Oct 18; 8(11):e79538. PubMed ID: 24260245
    [Abstract] [Full Text] [Related]

  • 65. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice.
    Gozar MM, Price VL, Kaslow DC.
    Infect Immun; 1998 Jan 18; 66(1):59-64. PubMed ID: 9423839
    [Abstract] [Full Text] [Related]

  • 66. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.
    Coelho CH, Gazzinelli-Guimaraes PH, Howard J, Barnafo E, Alani NAH, Muratova O, McCormack A, Kelnhofer E, Urban JF, Narum DL, Anderson C, Langhorne J, Nutman TB, Duffy PE.
    Vaccine; 2019 Feb 14; 37(8):1038-1045. PubMed ID: 30685251
    [Abstract] [Full Text] [Related]

  • 67. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 68. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV, Biswas S, Pillai CR, Saxena RK.
    Vaccine; 2008 Aug 18; 26(35):4526-35. PubMed ID: 18590786
    [Abstract] [Full Text] [Related]

  • 69. A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.
    Karen KA, Deal C, Adams RJ, Nielsen C, Ward C, Espinosa DA, Xie J, Zavala F, Ketner G.
    Infect Immun; 2015 Jan 18; 83(1):268-75. PubMed ID: 25368113
    [Abstract] [Full Text] [Related]

  • 70. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.
    Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, Shiloach J, Robbins JB, Schneerson R.
    Proc Natl Acad Sci U S A; 2007 Jan 02; 104(1):293-8. PubMed ID: 17190797
    [Abstract] [Full Text] [Related]

  • 71. Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose.
    Huang WC, Deng B, Mabrouk MT, Seffouh A, Ortega J, Long C, Miura K, Wu Y, Lovell JF.
    Malar J; 2020 Aug 28; 19(1):309. PubMed ID: 32859199
    [Abstract] [Full Text] [Related]

  • 72. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
    Venkatraman N, Anagnostou N, Bliss C, Bowyer G, Wright D, Lövgren-Bengtsson K, Roberts R, Poulton I, Lawrie A, Ewer K, V S Hill A.
    Vaccine; 2017 Oct 27; 35(45):6208-6217. PubMed ID: 28941620
    [Abstract] [Full Text] [Related]

  • 73. The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.
    Cheru L, Wu Y, Diouf A, Moretz SE, Muratova OV, Song G, Fay MP, Miller LH, Long CA, Miura K.
    Vaccine; 2010 Jun 17; 28(27):4423-9. PubMed ID: 20434549
    [Abstract] [Full Text] [Related]

  • 74. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, Tachibana M, Torii M, Tsuboi T, Arakawa T.
    Vaccine; 2011 Mar 24; 29(15):2720-6. PubMed ID: 21315699
    [Abstract] [Full Text] [Related]

  • 75. Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination.
    Duffy PE.
    Expert Rev Vaccines; 2021 Feb 24; 20(2):185-198. PubMed ID: 33478283
    [Abstract] [Full Text] [Related]

  • 76. Strategies & recent development of transmission-blocking vaccines against Plasmodium falciparum.
    Chaturvedi N, Bharti PK, Tiwari A, Singh N.
    Indian J Med Res; 2016 Jun 24; 143(6):696-711. PubMed ID: 27748294
    [Abstract] [Full Text] [Related]

  • 77. Cd loop fusion enhances the immunogenicity and the potential transmission blocking activity of Plasmodium falciparum generative cell specific 1 (GCS1) antigen.
    Nourani L, Ayoub Meigouni M, Afzali S, Zargar M, Pourhashem Z, Yousefi H, Sani JJ, Vand-Rajabpour H, Pirahmadi S, Raz A, Abouie Mehrizi A.
    Biochem Biophys Res Commun; 2024 Nov 12; 733():150599. PubMed ID: 39208643
    [Abstract] [Full Text] [Related]

  • 78. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles.
    Kumar R, Ledet G, Graves R, Datta D, Robinson S, Bansal GP, Mandal T, Kumar N.
    Pharm Res; 2015 Dec 12; 32(12):3827-36. PubMed ID: 26113235
    [Abstract] [Full Text] [Related]

  • 79. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.
    LeBlanc R, Vasquez Y, Hannaman D, Kumar N.
    Vaccine; 2008 Jan 10; 26(2):185-92. PubMed ID: 18054817
    [Abstract] [Full Text] [Related]

  • 80. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines.
    Duffy PE, Kaslow DC.
    Infect Immun; 1997 Mar 10; 65(3):1109-13. PubMed ID: 9038325
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.